# An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

> **NCT06734078** · — · ACTIVE_NOT_RECRUITING · sponsor: **IRCCS Azienda Ospedaliero-Universitaria di Bologna** · enrollment: 100 (actual)

## Conditions studied

- DLBCL - Diffuse Large B Cell Lymphoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06734078
- **Lead sponsor:** IRCCS Azienda Ospedaliero-Universitaria di Bologna
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-05-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06734078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06734078, "An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06734078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*